Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes

Abstract Recent studies have shown that high-risk patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have improved cardiovascular (CV) outcomes. In an exploratory analysis of data from the EMPA-REG study, elevations in haematocrit were shown...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jens Aberle, Markus Menzen, Sebastian M. Schmid, Christoph Terkamp, Elmar Jaeckel, Katja Rohwedder, Markus F. Scheerer, John Xu, Weifeng Tang, Andreas L. Birkenfeld
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/4ef2b8e15fa34ef09f3620b326bc5c84
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares